Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy

Journal of Controlled Release

Volumn 114, Issue 3, 2006, Pages 334-342

  Youn, Yu Seok ^a   Jung, Ju Young ^a   Oh, Seung Hyun ^a   Yoo, Sun Dong ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Caco 2 cell; Calcitonin; Hypocalcemic efficacy; Intestinal delivery; PEGylation; Permeability

Indexed keywords

CELL MEMBRANES; MOLECULAR STRUCTURE; PHARMACOKINETICS; TISSUE;

CACO-2 CELL; HYPOCALCEMIC EFFICACY; PEGYLATION; PERMEABILITY;

PROTEINS;

CYCLIC AMP; INTESTINE ENZYME; IODINE 125; LYSINE DERIVATIVE; MACROGOL 2000; MACROGOL DERIVATIVE; PANCREAS ENZYME; PEPTIDASE; SALCATONIN;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CELL TRANSPORT; CHEMICAL MODIFICATION; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; ENZYMATIC DEGRADATION; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; HYPOCALCEMIA; INTESTINE ABSORPTION; INTESTINE BRUSH BORDER; INTESTINE SECRETION; ISOMER; ISOTOPE LABELING; MALE; MEMBRANE PERMEABILITY; MOLECULAR SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SYSTEMIC CIRCULATION; TISSUE DISTRIBUTION;

ANIMALS; CACO-2 CELLS; CALCITONIN; CALCIUM; DRUG CARRIERS; DRUG STABILITY; HUMANS; INTESTINES; LYSINE; MALE; MICE; MICE, INBRED ICR; PERMEABILITY; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 33748151944     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.06.007     Document Type: Article

References (39)

1. 1.7]-eel calcitonin from various mucosal administration sites. J. Control. Release 76 (2001) 363-374
2. Guggi D., and Bernkop-Schnurch A. In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int. J. Pharm. 252 (2003) 187-196
3. Guggi D., Krauland A.H., and Bernkop-Schnurch A. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage from for salmon calcitonin. J. Control. Release 92 (2003) 125-135
4. Sinko P.J., Lee Y.-H., Makhey V., Leesman G.D., Sutyak J.P., Yu H., Perry B., Smith C.L., Hu P., Wagner E.J., Falzone L.M., McWhorter L.T., Gilligan J.P., and Stern W. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pham. Res. 16 (1999) 527-533
5. Lee V.H.L., and Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. 4 (1989) 171-207
6. Lee Y.-H., and Sinko P.J. Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 42 (2000) 225-238
7. Goldverg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 (2003) 289-295
8. Song K.-H., Chung S.-J., and Shim C.-K. Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control. Release 84 (2002) 27-37
9. Garcia-Fuentes M., Prego C., Torres D., and Alonso M.J. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25 (2005) 133-143
10. Bernkop-Schnurch A., Kast C.E., and Guggi D. Permeation enhancing polymer in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J. Control. Release 93 (2003) 95-103
11. Yamamoto A., Taniguchi T., Rikyuu K., Tsuji T., Fujita T., Murakami M., and Muranishi S. Effect of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 (1994) 1496-1500
12. Fujita T., Fujita T., Morikawa K., Tanaka H., Iemura O., Yamamoto A., and Muranishi S. Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids: synergistic effects of acylation and absorption enhancers. Int. J. Pharm. 134 (1996) 47-57
13. Wang J., Chow D., Heiati H., and Shen W.-C. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release 88 (2003) 369-380
14. Ramanathan S., Qiu B., Pooyan S., Zhang G., Stein S., Leibowitz M.J., and Sinko P.J. Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide. J. Control. Release 77 (2001) 199-212
15. Lee W.-K., Park J.-Y., Jung S., Yang C.-W., Kim W.-U., Kim H.-Y., Park J.-H., and Park J.-S. Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J. Control. Release 105 (2005) 77-88
16. Jensen-Pippo K.E., Whitcomb K.L., DePrince R.B., Ralph L., and Habberfield A.D. Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharm. Res. 13 (2006) 102-107
17. Caliceti P., Salmaso S., Walker G., and Bernkop-Schnurch A. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22 (2004) 315-323
18. Morcol T., Nagappan P., Nerenbaum L., Mitchell A., and Bell S.J.D. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277 (2004) 91-97
19. Collnot E.-M., Baldes C., Wempe M.F., Hyatt J., Navarro L., Edgar K.J., Schaefer U.F., and Lehr C.-M. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release 111 (2006) 35-40
20. Komarova S.V., Shum J.B., Paige L.A., Sims S.M., and Dixon S.J. Regulation of osteoclasts by calcitonin and amphiphilic calcitonin conjugates: role of cytosolic calcium. Calcif. Tissue Int. 73 (2003) 265-273
21. Clement S., Still J.G., Kosutic G., and McAllister R.G. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effect of HIM2. Diabetes Technol. Ther. 4 (2002) 459-466
22. Kipnes M., Dandona P., Tripathy D., Still J.G., and Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26 (2003) 421-426
23. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae S.Y., Byun Y., and Lee K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 16 (2005) 377-382
24. Lee H., Jang I.H., Ryu S.H., and Park T.G. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20 (2003) 818-825
25. Lee K.C., Moon S.C., Park M.O., Lee J.T., Na D.H., Yoo S.D., Lee H.S., and DeLuca P.P. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 16 (1999) 813-818
26. Lee K.C., Tak K.K., Park M.O., Lee J.T., Woo B.H., Yoo S.D., Lee H.S., and DeLuca P.P. Preparation and characterization of polyethylene glycol modified salmon calcitonins. Pharm. Dev. Technol. 4 (1999) 269-275
27. Mansoor S., Youn Y.S., and Lee K.C. Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect. Pharm. Dev. Technol. 10 (2005) 389-396
28. Lee K.C., Park M.O., Na D.H., Youn Y.S., Lee S.D., Yoo S.D., Lee H.S., and DeLuca P.P. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. Calcif. Tissue Int. 73 (2003) 545-549
29. Yoo S.D., Jun H., Shin B.S., Lee H.S., Park M.O., DeLuca P.P., and Lee K.C. Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonin. Chem. Pharm. Bull. 48 (2000) 1921-1924
30. Na D.H., Youn Y.S., Park E.J., Lee J.M., Cho O.R., Lee K.R., Lee S.D., Yoo S.D., DeLuca P.P., and Lee K.C. Stability of PEGylated salmon calcitonin in nasal mucosa. J. Pharm. Sci. 93 (2004) 256-261
31. Youn Y.S., Na D.H., Yoo S.D., Song S.-C., and Lee K.C. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29). J. Chromatogr., A 1061 (2004) 45-49
32. Na D.H., Park M.O., Choi S.Y., Kim Y.S., Lee S.S., Lee H.S., Yoo S.D., and Lee K.C. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Chromatogr., B 754 (2001) 259-263
33. Katayama T., Furuya M., Yamaichi K., Konishi K., Sugiura N., Murafuji H., Magota K., Saito M., Tanaka S., and Oikawa S. Discovery of a non-peptide small molecule that selectively mimics the biological actions of calcitonin. Biochim. Biophys. Acta 1526 (2001) 183-190
34. 125I-GST-TatdMt possessing potent anti-obesity activity. Regul. Pept. 129 (2005) 25-30
35. Youn Y.S., Na D.H., Yoo S.D., Song S.-C., and Lee K.C. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int. J. Biochem. Cell Biol. 37 (2005) 1525-1533
36. Hirai S., Yasbiki T., and Mima H. Effect of surfactants to nasal absorption of insulin in rats. Int. J. Pharm. 9 (1994) 165-172
37. Siegel E.G., Gallwitz B., Scharf G., Mentlein R., Morys-Wortmann C., Folsch U.R., Schrezenmeir J., Drescher K., and Schmidt W.E. Biological activity of GLP-1-analogues with N-terminal modifications. Regul. Pept. 79 (1999) 93-102
38. 18-mono-PEGylated salmon calcitonin. AAPS J. 6 S1 (2004) T2162
39. Azria M. The Calcitonins: Physiology and Pharmacology (1989), Karger, Basel